U.S. death rate from cancer is dropping

Source: www.webpronews.com Author: Sean Patterson Though cancer hasn’t been completely cured, it’s clear that treatments for the disease have improved over the past two decades. A yearly report from the American Cancer Society has shown that the death rate from cancer in the U.S. is declining among all Americans and for the most common types of cancer. The report, published recently in the Journal of the National Cancer Institute, shows that the death rate from all cancers combined has been falling since the early 1990. From 2000 to 2009, combined cancer death rates have fallen an average of 1.8% among men and 1.4% among women. Black men and black women saw the largest declines in cancer deaths from 2000 to 2009, though their cancer death rates from 2005 to 2009 were still highest when compared to other racial groups. Though death rates for cancers such as lung cancer , breast cancer, and colon cancer are declining, the rate of diagnoses for some cancers is increasing. The rate of new cases of pancreas, kidney, thyroid, liver, melanoma, and myeloma cancers have all increased in men from 2000 to 2009. For women, rates of new cases of thyroid, melanoma, kidney, pancreas, liver, leukemia, and uterus cancers increased during the same period. The report points out that excess weight and lack of physical activity are risk factors for many of these cancers. “The continuing drop in cancer mortality over the past two decades is reason to cheer,” said John Seffrin, CEO of the [...]

HPV DNA, E6?I-mRNA expression and p16(INK4A) immunohistochemistry in head and neck cancer – how valid is p16(INK4A) as surrogate marker?

Source: HighWire- Stanford University It has been proposed that p16(INK4A) qualifies as a surrogate marker for viral oncogene activity in head and neck cancer (HNSCC). By analyzing 78 HNSCC we sought to validate the accuracy of p16(INK4A) as a reliable marker of active HPV infections in HNSCC. To this end we determined HPV DNA (HPVD) and E6?I mRNA (HPVR) expression status and correlated these results with p16(INK4A) staining. In tonsillar SCC 12/20 were HPVD+ and 12/12 of these showed active HPV infections whereas in non-tonsillar SCC 10/58 were HPVD+ and 5/10 showed active HPV infections. Thus, we prove about 8% of non-tonsillar SCC to be also correlated with HPV-associated carcinogenesis. Strikingly, 3/14 (21.4%) of tonsillar and non-tonsillar HPVD+/HPVR+ cases did not show p16(INK4A) overexpression and these cases would have been missed when applying initial p16(INK4A) staining only. However, in 13 cases negative for HPV, DNA p16(INK4A) was overexpressed. In conclusion, our data confirm tonsillar SCC to be predominantly but not only associated with active HPV infections. Furthermore, our data show that p16(INK4A) overexpression is not evident in a subgroup of HNSCC with active HPV infection. Definitive HPV data should therefore be utilised in diagnostics and treatment modalities of HPV positive and HPV negative HNSCC patients, resulting in a paradigm shift regarding these obviously different tumour entities. This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

2012-04-17T12:58:24-07:00April, 2012|Oral Cancer News|
Go to Top